Association of tirzepatide with reverse cardiac remodeling and improved diastolic function in obesity-related HFpEF: A prospective real-world cohort study.

Studied

A prospective observational study tracked heart structure and function after tirzepatide was started in routine care.

Who / model

Fifty adults at one centre had obesity-related heart failure with preserved pumping function. Median follow-up was 5.8 months; changes were compared with their own starting measurements.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

The two primary measures improved: left-ventricular mass fell 12.4 grams and an ultrasound estimate of heart-filling pressure fell 1.45 units. Other outcomes included walking 43 metres farther in six minutes and improved symptom class in 60%. These were before-and-after associations.

Limits

Study limitations were not stated in the abstract. Methodological quality has not been appraised.

Read summary source ↗ · Prepared 9/15/2026 · AI-assisted, source-based summary